| |
Coha; Nice crystal ball. When you said:
"I don't expect a *change* in focus. Clearly, however, there will be more time now to focus on the other parts of the strategy, namely selling the niche products. That is the absolute number 1 priority now, bar none. Get $$ onto the books now and begin a cash flow."
You weren't kidding in light of today's announcement
ProCyte Corporation (Nasdaq: PRCY - news) today said that it has received FDA 510(k) medical device clearance to market two new innovative products -- OsmoCyte(R) Island wound care dressings for the care and management of chronic and acute wounds, and Pillo(TM) Pro dressings for use in the cosmetic surgery and dermatology markets.
OsmoCyte(R) Island wound dressings are self-adhesive, high-tech dressings. Their unique, highly absorptive hydropolymer pad collects wound fluid by locking it into the dressing's molecular structure. This dynamic process prevents the fluid from leaking and damaging healthy surrounding tissue -- a frequently reported problem.
The OsmoCyte(R) Island dressing is designed for one-step application and easy removal -- an added benefit for at-home use and care. The dressing's ability to absorb substantial amounts of moisture make it well suited for use in the expanding home healthcare markets and for nursing home care.
ProCyte's second new product, the Pillo(TM) Pro dressing, is a related, super-absorptive polymer dressing designed specifically to meet the needs of the cosmetic surgery market. The Pillo(TM) Pro dressing controls excessive drainage of liposuction and other surgical wounds -- and virtually eliminates leakage into post-surgical garments.
The dressing design makes it ideal for use in a number of additional cosmetic surgery procedures, including wound or burn care
associated with face lifts, chemical or laser skin resurfacing procedures and dermabrasions. Together with liposuction, these
surgical treatments represent over one million procedures estimated to be performed annually in the United States alone.
''In keeping with ProCyte's strategic direction, we will focus on the niche cosmetic surgery and dermatology markets,'' said
Jack Clifford, ProCyte's president and chief executive officer. ''We expect to continue to build product line synergy with our
GraftCyte(TM) System, Iamin(R) Post Laser Creme and related products. And we will look to partners to market our
differentiated wound care products to the hospital, extended care and nursing home sectors.'' |
|
